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ABSTRACT: We report a global quantitative phosphopro-
teomic study of bloodstream and procyclic form Trypanosoma
brucei using SILAC labeling of each lifecycle stage. Phos-
phopeptide enrichment by SCX and TiO2 led to the identification
of a total of 10096 phosphorylation sites on 2551 protein groups
and quantified the ratios of 8275 phosphorylation sites between
the two lifecycle stages. More than 9300 of these sites (92%) have
not previously been reported. Model-based gene enrichment
analysis identified over representation of Gene Ontology terms
relating to the flagella, protein kinase activity, and the regulation
of gene expression. The quantitative data reveal that differential
protein phosphorylation is widespread between bloodstream and
procyclic form trypanosomes, with significant intraprotein dif-
ferential phosphorylation. Despite a lack of dedicated tyrosine kinases, 234 phosphotyrosine residues were identified, and these
were 3−4 fold over-represented among site changing >10-fold between the two lifecycle stages. A significant proportion of the
T. brucei kinome was phosphorylated, with evidence that MAPK pathways are functional in both lifecycle stages. Regulation of
gene expression in T. brucei is exclusively post-transcriptional, and the extensive phosphorylation of RNA binding proteins
observed may be relevant to the control of mRNA stability in this organism.
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■ INTRODUCTION
The protozoan parasite Trypanosoma brucei is the etiological
agent of African sleeping sickness, also known as Human African
Trypanosomiasis (HAT), which is transmitted by the bite of an
infected tsetse fly. The disease is usually fatal if left untreated
and is estimated to be responsible for around 10000 deaths per
annum in sub-Saharan Africa.1 Current treatments are expensive,
toxic and difficult to administer, leaving an urgent unmet need for
new therapeutic agents.2 T. brucei has a complex digenetic lifecycle
between an insect vector and a mammalian host, and its ability
to adapt its proteome to these disparate environments is essential
to its survival and virulence. During the early stages of an infection,
the clinically relevant bloodstream form of the parasite proliferates
in the blood and lymph of the human host, then in the second
stage enters the cerebral-spinal fluid and brain, resulting in coma
and death. When a tsetse fly feeds on an infected host, the parasite
is ingested with the blood meal, triggering parasite differentiation
into the procyclic form to enable survival in its new environment.
Both the procyclic form and bloodstream form of the parasite
may be cultured in vitro. We have recently quantified the changes
in protein expression between the procyclic and bloodstream form
lifecycle stages using SILAC labeling of procyclic cells, demon-
strating that about 10% of the observed proteome is differentially
regulated by more than 5-fold.3 The fold-change in protein
level showed a strong correlation (Pearson correlation 0.86) to
changes in mRNA level recorded by transcriptomic studies,4
despite the atypical mechanism of gene expression in trypanosomes,
where genes are transcribed in large polycistronic units that are
trans-spliced into mature mRNAs for translation, with mRNA
abundance controlled by stability.5
There is evidence that protein phosphorylation may be im-
portant in T. brucei; Nett et al. used sequential strong-cation
exchange (SCX) and TiO2 enrichment of phosphopeptides
derived from the cytosolic fraction of bloodstream form parasites
to identify 1204 phosphorylation sites on 491 proteins,6 and
immunoprecipitation with antiphosphotyrosine antibodies to
identify 34 phosphotyrosine sites induced in response to the
treatment of procyclic form cells with hydrogen peroxide.7
However, to date, there has been no quantitative comparison of
the phosphoproteomes of the two lifecycle stages. We set out
to define the global protein phosphorylation status of the two
lifecycle stages to explore the biological processes that might be
modulated by phosphorylation, and to highlight stage-specific
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phosphorylation changes. Here, we report a global quantitative
phosphoproteomic study of bloodstream and procyclic form
Trypanosoma brucei using SILAC labeling of each lifecycles
stage that identifies 9314 previously unidentified phosphorylation
sites. The results show that differential phosphorylation is wide-
spread between the procyclic and bloodstream form and that it
adds significant complexity to the changes in the proteome.
■ EXPERIMENTAL SECTION
Cell Culture Media
HMI9-T, a modification of the original IMDM-based HMI-9,8
uses 56 μM 1-thioglycerol in place of 200 μM 2-mercaptoethanol,
2 mM glutaMAX I (Invitrogen) in place of 4 mM L-glutamine, and
contains 10% heat-inactivated fetal bovine serum (PAA). Similarly,
HMI11-T is a modification of the original HMI11 (HMI-9 lacking
serum plus)8 that use 56 μM 1-thioglycerol and 2 mM glutaMAX
I with 10% heat-inactivated fetal bovine serum.
HMI11-SILAC − RK was prepared in the same way as HMI11-T
but using IMDM depleted of L-Arginine, L-Lysine (Sigma) and
10% dialyzed heat-inactivated fetal bovine serum (10 kDa
molecular weight cutoff, PAA) and was supplemented with 4 mg/L
folic acid. The HMI11-SILAC − RK was supplemented with
either normal L-Arginine and L-Lysine (HMI11-SILAC + R0K0),
or with L-Arginine U−13C6 and L-Lysine 4,4,5,5-2H4 (HMI11-
SILAC + R6K4, Cambridge Isotope Laboratories) at 30% of the
original HMI11 concentration (120 and 240 μM respectively)
unless otherwise stated. Original SDM-79 medium9 and SILAC
SDM-79 medium (SDM-79 + R6K6) were prepared as described
previously.3
Cell Culture
Procyclic form Trypanosoma brucei Lister 427 clone 29.13.6
cells were grown at 28 °C without CO2 in SDM-79 in the
presence of 15 μg/mL G418 and 50 μg/mL hygromycin.
Culture adapted strain Lister 427 monomorphic bloodstream
form T. brucei (MITat 1.2, expressing VSG221) were cultured
in HMI-9T containing 2.5 μg/mL G418 at 37 °C in a 5% CO2
incubator. Both cell lines have been genetically modified to
express the T7 RNA polymerase and the tetracycline repressor
protein, as described by Wirtz et al.10 Cell dimensions were
measured using a CASY cell counter.
For the growth curves, the T. brucei bloodstream form cells
were washed twice in 10 mL HMI11-SILAC − RK and re-
suspended at 5 × 104 cells/mL in either HMI-9T or HMI11-
SILAC supplemented with R0K0 at 30% of the original HMI11
concentration. Cells were counted using a Neubauer chamber
and phase contrast microscope, and the cultures were diluted
100-fold every two days. After 10 days samples were collected for
analysis by light microscopy.
For SILAC labeling, T. brucei bloodstream form log-phase
cells were diluted 10000-fold into HMI11-SILAC + R6K4. Cells
were harvested after 3 days growth at 2.5 × 106 cells/mL.
SILAC labeling of T. brucei procyclic form cells was performed
in SDM-79 + R6K6 as described previously.
3
Cells were harvested by centrifugation and hypotonically
lysed at 5 × 109 cells/mL for 5 min on ice in the presence 0.1 μM
1-chloro-3-tosylamido-7-amino-2-heptone (TLCK), 1 mM benza-
midine, 1 mM phenyl-methyl sulfonyl fluoride (PMSF),
1 μg/mL leupeptin, 1 μg/mL aprotinin and Phosphatase Inhi-
bitor Mixture II (Calbiochem). The protein concentration was
determined by BCA assay (Pierce) to be ∼5 mg/mL from each
cell type. Samples were aliquoted, snap frozen, and stored at
−80 °C prior to subsequent processing.
Microscopy
Bloodstream form cells at late log phase grown in either HMI9-T
or HMI11-SILAC + R0K0 for 10 days were washed in 10 mL
phosphate buffer saline at 800 × g at 4 °C, fixed in 4% paraform-
aldehyde in phosphate buffered saline at 4 °C for 30 min, and
placed on a coverslip. After air-drying the coverslips were washed
in phosphate buffered saline and mounted onto slides. The phase
contrast images were collected in a Zeiss Axioplan microscope.
Estimating Efficiency of SILAC Labeling
Bloodstream form cells were grown in HMI11-SILAC + R6K4
for 11−12 cell divisions and hypotonically lysed as described
above. To reduce the sample complexity the proteins were frac-
tionated by SDS-PAGE, and a band corresponding to 25−50 kDa
molecular weight range was excised and subjected to in-gel tryptic
digest prior to analysis by LC−MS/MS. Ten peptides were chosen
at random and the relative abundance of the major isotopic
peak of heavy (arginine-13C6/lysine-
2H4) and light (argini-
ne-12C6/lysine-
1H4) forms were measured using the extracted
ion chromatogram function in Excalibur (Thermo Scientific).
Rodent Infectivity Studies
Bloodstream form cells were grown in HMI9-T or HMI11-
SILAC + R0K0 for >14 days prior to inoculation of female Balbc
mice (three per condition) by inter peritoneal injection of
1 × 103, 1 × 104 or 1 × 105 cells in the same media. Daily tail
bleeds were used to monitor the number of parasites in the
bloodstream using a heamocytometer, and animals were euthanized
when the parasite burden exceeded 5 × 108 cells/mL prior to overt
distress.
Comparative Proteomic Analysis
A 1:1 mix of procyclic form cells grown in light-SILAC media
and bloodstream form cells grown in heavy-SILAC media was
solubilized with SDS and tryptic peptides were generated by
FASP. Peptides were fractionated by SCX prior to analysis by
liquid chromatography tandem mass spectrometry as described
previously,3 except only 6 SCX fractions were analyzed and
technical duplicates were not performed. The previously re-
ported the analysis of a 1:1 mix of procyclic form cells grown in
heavy-SILAC media and bloodstream form cells grown in light-
SILAC media, consisting of technical duplicates of eight SCX
fractions and ten SDS-PAGE fractions,3 was reprocessed to en-
sure accurate comparison with the current data.
Filter Aided Sample Preparation
Peptide samples for analysis by mass spectrometry were pre-
pared by modification of the filter-aided sample preparation
procedure (FASP).11 Briefly, samples were defrosted and com-
bined according to the experiment design to give a total of 2.5 × 109
lysed cells (0.5 mL), solubilized with 4% SDS and then reduc-
tively alkylated in a 30000 molecular weight cutoff vertical spin
filtration unit (Vivascience) using the FASP procedure adapted
for the larger volumes used here. The sample was digested with
1:100 ratio (w/w) of trypsin gold (Promega) in the filtration
unit for 18 h at 37 °C, tryptic peptides were eluted by centri-
fugation, and the filter washed sequentially with 1 mL of 50 mM
NH4HCO3 and 1 mL of 0.5 M NaCl. The combined eluent
was desalted using a 500 mg C18 cartridge (SepPak, Waters) and
lyophilized.
Strong Cation Exchange Chromatography
Strong cation exchange (SCX) was performed on an Agilent
1120 compact LC using a 3.0 × 200 mm 5 μm polysulfethyl
aspartamide column (Poly LC) with a flow rate of 350 μL/min
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and detection at 220 nm. Phosphopeptides were enriched using
the method of Beausoleil et al.12 Dried peptides were dissolved
in 200 μL of solvent A (5 mM KHPO4 pH 2.7, 30% MeCN)
and separated by salt gradient consisting of 5 min at 100% solvent
A, a 15 min gradient to 15% solvent B (solvent A + 0.35 M KCl),
1 min gradient to 100% B, 15 min at 100% B, and a 5 min
gradient to 100% A. Fractions of 0.7 mL were collected throughout
the run and combined into 8 fractions of equal peptide content
based on their absorbance at 220 nm. Combined fractions were
lyophilized prior to TiO2 enrichment.
TiO2 Enrichment of Phosphopeptides
Phosphopeptides were enriched using TiO2 in batch mode in
the presence of 5% TFA and 1 M glycolic acid.13 Briefly,
lyophilized peptides were resuspended in 80% MeCN, 5% TFA,
1 M glycolic acid prior to incubation for 15 min with TiO2
beads (GL Sciences) that were prewashed in the same solution.
Beads were recovered by centrifugation at 700 × g for 1 min,
washed three times in 80% MeCN, 5% TFA and eluted twice in
0.6% NH3 (aq). The combined eluents were lyophilized and
stored at −20 °C prior to analysis.
Mass Spectrometry Data Acquisition
Liquid chromatography tandem mass spectrometry was per-
formed by the FingerPrints Proteomic Facility at the University
of Dundee. Liquid chromatography was performed on a fully
automated Ultimate U3000 Nano LC System (Dionex) fitted
with a 1 × 5 mm PepMap C18 trap column and a 75 μm × 15 cm
reverse phase PepMap C18 nanocolumn (LC Packings, Dionex).
Samples were loaded in 0.1% formic acid (buffer A) and
separated using a binary gradient consisting of buffer A (0.1%
formic acid) and buffer B (90% MeCN, 0.08% formic acid).
Peptides were eluted with a linear gradient from 5 to 40%
buffer B over 65 min. The HPLC system was coupled to an
LTQ Orbitrap Velos Pro mass spectrometer (Thermo Scientific)
equipped with a Proxeon nanospray ion source. For phos-
phoproteomic analysis, the mass spectrometer was operated in
data dependent mode to perform a survey scan over a range
335−1800 m/z in the Orbitrap analyzer (R = 60000), with each
MS scan triggering 15 MS2 acquisitions of the 15 most intense
ions using multistage activation on the neutral loss of 98 and
49 thomsons in the LTQ ion trap.14 The Orbitrap mass ana-
lyzer was internally calibrated on the fly using the lock mass of
polydimethylcyclosiloxane at m/z 445.120025.
For proteomic analysis, the HPLC gradient was increased to
145 min and the mass spectrometer was operated in data dependent
mode with each MS scan triggering 15 MS2 acquisitions of the
15 most intense ions in the LTQ ion trap.
Data Processing
Data was processed using MaxQuant15 version 1.3.0.5 which
incorporates the Andromeda search engine.16 Proteins were
identified by searching a protein sequence database containing
T. brucei brucei 927 annotated proteins (Version 4.0, downloaded
from TriTrypDB,17 http://www.tritrypdb.org/) supplemented
with the VSG221 sequence and frequently observed contam-
inants (porcine trypsin, bovine serum albumins and mammalian
keratins) that contains a total of 10,081 protein sequences. Search
parameters specified an MS tolerance of 6 ppm, an MS/MS
tolerance at 0.5 Da and full trypsin specificity, allowing for up
to two missed cleavages. Carbamidomethylation of cysteine
was set as a fixed modification and oxidation of methionines,
N-terminal protein acetylation and N-pyroglutamate were allowed
as variable modifications. Phosphoproteomic analysis included
phosophorylation of serine, threonine and tyrosine as additional
variable modifications. Peptides were required to be at least 7
amino acids in length and a MaxQuant score >5, with false dis-
covery rates (FDRs) of 0.01 calculated at the levels of peptides,
proteins and modification sites based on the number of hits
against the reversed sequence database. SILAC ratios were cal-
culated using only peptides that could be uniquely mapped to a
given protein group, and required a minimum of two SILAC
pairs. To account for any errors in the counting of the number
of cells mixed, the distribution of SILAC ratios was normalized
within MaxQuant at the peptide level so that the median of log2
ratios is zero, as described by Cox et al.15
Prior to statistical analysis, the outputs from MaxQuant were
filtered to remove known contaminants and reverse sequences,
and phosphorylation sites with a MaxQuant localization pro-
bability <0.95 were discarded. This localization probability cut
off was chosen following the manual inspection of the tandem
mass spectra showing the best localization evidence for phos-
phorylation sites occurring on protein kinases.
Quantitation of the changes in abundance are derived from
the two SILAC labeled experiments with a 1:1 mix of procyclic
form cells grown in heavy-SILAC media and bloodstream cells
grown in light-SILAC media, and the label swap experiment
with the SILAC labeling reversed. SILAC ratios for phos-
phorylation sites were calculated using only data from the
phosphoproteomic experiments, and SILAC ratios for proteins
were calculated using only data from the nonenriched pro-
teomic experiments. When SILAC ratios were reported in both
label swap experiments, replicate trimming was applied by cal-
culating the mean and standard deviation σ of the distribution
of the log2 (H/L × L/H), and discarding data >2σ from the
mean (Figure 3).18 Where SILAC ratios were reported in only
one experiment, they were discarded if the percentage variation
in the calculated SILAC ratio (calculated by MaxQuant) was
>100%.
The Mascot Delta Score was calculated by determining the
difference between the best and second best Mascot ion scores
for alternative phosphorylation site localizations on an other-
wise identical peptide sequence,19 and appended to the MaxQuant
outputs. Mascot distiller was used to peak pick mass spectra and
read the centroid data from raw tandem mass spectra and submit
searches to Mascot (Server version 2.2) using the same sequence
database, enzyme specificity, modifications and mass tolerance as
described above.
Data was visualized using Perseus 1.3.0.4 (www.perseus-
framework.org) and further information on the identified proteins
was obtained from TriTrypDB (http://www.tritrypdb.org).17
Gene ontology (GO) term enrichment was carried out using
model based gene set analysis or term for term enrichment in
Ontologiser20 using a T. brucei specific GO set containing
16765 terms for 4340 genes obtained from GeneDB (http://
www.genedb.org).21 To make our data accessible to the scientific
community, we uploaded our study to TriTrypDB and de-
posited the Thermo RAW files and search engine output into
ProteomeXchange (http://www.proteomexchange.org) acces-
sion number PXD000049, enabling researchers to access the
data presented here.
■ RESULTS
SILAC Labeling of Bloodstream Form Trypanosoma brucei
To enable SILAC labeling of bloodstream form T. brucei cells, a
modified medium was created based on HMI11-T (HMI9-T
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lacking serum plus),8 where L-arginine and L-lysine could be
replaced by stable heavy isotope forms (HMI11-SILAC). As
bloodstream form cells are usually only cultured to <2 × 106
cells/ml, a 10-fold lower density than procyclic cells, we first set
out to establish labeling conditions that would reduce the
amount of label required and maximize the number of cells
obtained. We found that the growth of bloodstream form
T. brucei cells in HMI11-SILAC containing only 30% of the
normal concentration of L-arginine and L-lysine was equivalent
to cell growth in the HMI9-T medium generally used for
bloodstream form cell culture (Figure 1A). As expected, the
HMI11-SILAC medium failed to support cell growth in the
absence of L-arginine and L-lysine whereas cells were readily able to
grow to 5 × 106 cells/ml in the log−linear phase in the presence
of L-arginine and L-lysine (Figure 1B). Furthermore, the gross
morphology of the cells was unaffected after ten days in culture in
HMI11-SILAC + 30% L-arginine and L-lysine, as judged by light
microscopy (Figure 1C) and measurement of cell dimensions by
light scattering (Supplemental Table 1, Supporting Information).
Importantly, cells cultured in HMI11-SILAC + 30% L-arginine and
L-lysine for >14 days maintained infectivity in mice (Supplemental
Figure 1, Supporting Information). Taking all the above results
into consideration, we concluded that culture of bloodstream
form T. brucei in HMI11-SILAC + 30% L-arginine and L-lysine
is equivalent to culture in HMI9-T media.
To experimentally assess the efficiency of heavy isotope
incorporation in HMI11-SILAC, bloodstream form cells were
grown in HMI11-SILAC + R6K4 for 11−12 cell divisions and
extracted proteins subjected to analysis by LC−MS/MS. If heavy
isotope incorporation occurred only by dilution (neglecting
protein turnover), then 11−12 cell divisions should produce
>99.9% incorporation, but in reality will be limited by the
isotopic purity of the labeled amino acids. The heavy isotope
incorporation at steady state was estimated to be 98.5 ± 1.5%
by comparing the relative abundance of the major isotopic peak
of the heavy (arginine-13C6/lysine-
2H4) and light forms of ten
peptides chosen at random. No significant incorporation of
proline-13C5 (by conversion of arginine-
13C6) was observed
(Supplemental Figure 2, Supporting Information), as noted
previously for the procyclic form.3
Comparative Proteomic Analysis
A prerequisite for comparative quantitative phosphoproteomic
analyses is access to a relevant comparative quantitative pro-
teomic data with which to distinguish the different types of
quantitative phosphorylation differences (i.e., those that simply
track changes in protein levels, those that do not correlate with
changes in protein level and those that are unique to one or
other lifecycle stage). Our previous comparative SILAC pro-
teomic analysis of bloodstream grown in light medium and
procyclic form T. brucei grown in heavy medium gave us ratios
for 3553 proteins, and demonstrated that large changes in
specific protein abundance occur between the lifecycle stages.3
To improve the quality of this comparative quantitative proteome
data set, we exploited the development of SILAC labeling of
Figure 1. Growth of bloodstream form T. brucei in SILAC labeling media. Cells were grown in conventional HMI9-T medium or in the HMI11-
SILAC medium developed in this paper. (A) Cumulative growth over 10 days (with subculturing every 2−3 days). (B) Growth to stationary phase.
(C) Light microscopy of cells after 10 days in culture.
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bloodstream form trypanosomes, described above, to perform a
“label-swap” experiment using a 1:1 mix of procyclic form cells
grown in light-SILAC medium and bloodstream form cells grown
in heavy-SILAC medium. The combined cells were solubilized
with SDS, and the tryptic peptides generated by FASP were
fractionated by SCX prior to analysis as described previously,3
except that six SCX factions were used and a longer gradient
was applied for the LC−MS/MS analysis instead of running
technical duplicates. A total of 3780 proteins were identified,
with SILAC ratios determined for 3313 of them. The new label-
swap data set showed very good agreement with our published
SILAC data,3 with a comparable depth of coverage and a Pearson
correlation of 0.92 (Figure 3A). Given the good correlation be-
tween the two data sets, we combined them to provide a
definitive comparative quantitative proteome with which to
interpret our phosphoproteomic data.
Comparative Phosphoproteomic Strategy
The objective of this study was: (i) To define the phos-
phoproteome of procyclic form T. brucei for the first time; (ii)
To enhance the existing phosphoproteome of bloodstream
form T. brucei.6 (iii) To quantify the changes in phosphorylation
state which occur between the lifecycle stages using SILAC
methodology. Four separate phosphoproteomic experiments
were conducted (Figure 2) starting from: (i) Procyclic form
cells grown in light-SILAC medium. (ii) A 1:1 mix of procyclic
form cells grown in heavy-SILAC medium and bloodstream
form cells grown in light-SILAC medium. (iii) A “label swap”
experiment consisting of a 1:1 mix of bloodstream form cells
grown in light-SILAC medium and procyclic cells grown in
heavy-SILAC medium. (iv) Bloodstream form cells grown in
light-SILAC medium. To maximize coverage of membrane and
structural proteins, total protein extracts were prepared with 4%
SDS using the filter-aided sample preparation (FASP) procedure,11
resulting in near-complete solubilization of the parasites. After
denaturation and reductive alkylation the proteins were digested
with trypsin in solution. Resulting phosphopeptides were enriched
and fractionated into eight samples by SCX chromatography12
prior to further enrichment using TiO2 chromatography in batch
mode.13 For each phosphoproteomic experiment, the eight
fractions were analyzed by liquid chromatography tandem mass
spectrometry in technical triplicates on a LTQ Oribtrap Velos
using multistage acquisition.14
Overview of Data
The combined data were from a total of 138 LC−MS/MS runs,
with 96 runs for samples enriched for phosphopeptides and 88
for samples with SILAC labeling. Altogether 589101 MS/MS
spectra were identified, corresponding to 58087 nonredundant
peptide sequences belonging to 5478 protein groups with a
false discovery rate of 1% (Supplementary Tables S2 and S3,
Supporting Information). A total of 10096 phosphorylation
sites were identified on 2551 proteins (Supplementary Tables S4
and S5, Supporting Information), of which SILAC ratios could be
determined for 8275 phosphorylation sites on 2233 protein
groups, with a Pearson correlation of 0.78 between the label-
swap experiments. A total of 8120 phosphorylation sites on
2137 protein groups were also identified using Mascot software,
of which 6196 phosphorylation sites on 1933 protein groups
had a Mascot delta score ≥10, reported to give a 1% false
localization rate (FLR) for Orbitrap-MSA data.19 Of the 10096
phosphorylation sites identified by MaxQuant, 9314 (92%)
have not previously been reported. The data presented here there-
fore represents a major advance in the depth of the trypanosome
phosphoproteome.
The distribution of phosphorylation between residues was
found to be 8087 phosphoserine (pS) sites (80%), 1,720 phos-
phothreonine (pT) sites (17%), and 289 phosphotyrosine (pY)
sites (3%), in reasonable agreement with the T. brucei bloodstream
form cytosolic phosphoproteome observations of 75% pS, 21.5%
pT, 3.5% pY.6 Of the 10096 phosphorylation sites observed,
6493 occurred on 1491 proteins annotated as hypothetical or
hypothetical conserved, reflecting the high proportion of genes
of unknown function in the trypanosome genome. Gene Ontology
terms are associated with only 1310 out of the 2552 phos-
phoproteins we observed, limiting the power of GO term
enrichment analysis. Performing model based gene set analysis,20 a
method designed to give a high-level summarized view of the data,
identified only three terms: cilliary or flagella motility (GO:001539,
PEP 1), protein tyrosine kinase activity (GO:004713, PEP 0.7), and
regulation of gene expression (GO:0010468, PEP 0.5). This is
an intriguing outcome as the T. brucei genome lacks any
identifiable dedicated tyrosine kinases,6,22 yet has the associated
GO terms, illustrating the pitfalls of such analyses. Performing
term-for-term enrichment generated 45 significantly enriched
GO terms (p < 0.01, Figure 4) confirming the predominance of
terms associated with flagella motility, protein kinase activity
and regulation of gene expression, and revealing additional terms for
RNA, zinc and calmodulin binding (GO:0005488, GO:0008270,
GO:0005516), and peptidase activity (GO:0004181, GO:0004197).
Greater biological insight from the data is likely to come from the
community inspecting the phosphorylation patterns, and their
changes between lifecycle stages, of proteins of specific interest to
them, a few examples of which are provided below.
Figure 2. Phosphoproteomic workflow. Differentially labeled (heavy
and light) bloodstream and procyclic form trypanosomes were lysed in
SDS, and total proteins S-alkylated and digested with trypsin using the
FASP method. Phosphopeptides were separated into eight fractions by
SCX HPLC, enriched with TiO2, and analyzed by LC−MS/MS using
MSA.
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Comparison of the Phosphoproteomes of Bloodstream
and Procyclic Form T. brucei
SILAC labeling allows the fold-changes that occur between the
bloodstream and procyclic form of T. brucei (log2 Pcf/Bsf) to
be quantified at both the protein and phosphorylation site level.
As the phosphoproteomic workflow includes selective enrich-
ment for phosphorylated peptides, this data cannot be used in
the calculation of protein SILAC ratios, which are instead derived
from separate proteomic experiments. We were able to determine
fold-changes for a total of 8275 phosphorylation sites on 2233
protein groups, with 5768 (70%) of the phosphorylation sites on
1385 protein groups having ratios at both the protein- and site-
level. In general, the changes in phosphorylation site occupancy
between the lifecycle stages are greater than the changes in
protein levels; for example, 318 (5.5%) of the phosphorylation
sites change ≥10-fold (log2 ≥|3.32|) between lifecycle stages,
while only 33 (0.87%) of protein groups change ≥10-fold.
Indeed, plotting the fold-changes in protein ratio against the
fold-changes in phosphorylation site ratio (Figure 5A) reveals
that the observed changes are relatively weakly correlated (Pearson
correlation 0.49). However, there are numerous examples where:
(i) The change in phosphorylation correlates with the change in
protein abundance, suggesting that phosphorylation stoichiom-
etry is maintained between lifecycle stages in these cases. (ii)
The change in phosphorylation correlates negatively with the
change in protein abundance. (iii) Protein abundance is main-
tained but phosphorylation stoichiometry changes significantly
(both up and down). (iv) Different phosphorylation sites on
the same protein show a wide range of fold-changes (Figure 5B
and Figure 6). These data demonstrate that changes in protein
phosphorylation status between the lifecycle stages of T. brucei
Figure 3. Correlation of label-swap biological replicates. (A) Changes in protein abundance. (B) Changes in phosphorylation site abundance.
Replicates were trimmed at 2 σ prior to further analysis. Black squares <2 σ, gray square >2 σ.
Figure 4. Gene Ontology term enrichment for all observed phosphoproteins. Term-for-term enrichment, P < 0.01; white box, Biological process;
light gray box, Cellular component; dark gray box, Molecular function. For clarity parental terms are omitted; the complete graph can be found in the
Supporting Information (Figure S3).
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add significant complexity to the differential expression of the
proteome. Some individual cases are discussed in more detail below.
Manual validation of protein kinase phosphorylation sites
In order to judge the quality of the phosphorylation site assign-
ments, and to empirically assess the false localization rate, a
subset of the automated phosphorylation site assignments were
manually inspected (Figure 6 and Supporting Information).
The subset chosen was the T. brucei kinome consisting of 176
protein kinases22b as they are expected to occur at relatively low
abundance and to show physiologically relevant phosphorylation.
Using a MaxQuant localization score of ≥0.75 as an initial
cutoff, we identified 641 specific phosphorylation sites on 127
protein kinases (for comparison a cutoff of ≥0.95 gave 493 sites
on 124 kinases). Of these 641 automatically annotated sites on
127 kinases, 549 sites on 122 kinases were validated by manual
inspection (Supplemental Table S6, Supporting Information).
Overall, the manual validation correlated well with the sites
chosen using the MaxQuant localization score and the Mascot
delta score (MDS) methods.19 However, we noted that only
42% of sites in the MaxQuant localization score range 0.75−
0.95 were manually validated, whereas over 94% of the sites
MaxQuant localization score >0.95 were manually validated,
increasing to over 98% at a localization score of >0.99. Further,
at an MDS of 10, reported to give a global 1% false localiza-
tion rate for Orbitrap Velos − MSA data,19 we were able to
manually confirm 98% of the automatically annotated sites.
However, it is worth noting that 81% of sites with MDS < 10
and 66% of sitesidentified by MaxQuant but not by Mascot
were manually validated. Based on this manual survey of a
significant number of phosphorylation site assignments, we
have chosen to report all automatically annotated phosphor-
ylation sites with MaxQuant localization scores >0.95 (with an
estimated false localization rate of <6%).
Interestingly, the variation in the phosphorylation of the kinome
between the two lifecycles stages is lower than the general data
set, with only 15 phosphorylation sites showing a 10-fold or
greater change. The protein kinase A catalytic subunit isoform 1
(Tb09.211.2410) showed strongly up-regulated phosphoryla-
tion in the bloodstream form parasite at three sites (log2 range
−5.0 to −4.3), although the assignment of increased phosphor-
ylation in the putative activation loop at T179 (Log2 −2.6) is
slightly ambiguous as an identical (phospho)peptide is shared
by protein kinase A catalytic subunit isoform 2 (Tb09.211.2360).
Similarly, the protein kinase A regulatory subunit (Tb11.02.2210)
has 5 sites which are also up-regulated in the bloodstream form,
though to a lesser extent (log2 range −4.4 to −0.8). Protein
kinases with phosphorylation up-regulated in the procyclic form
include a NEK kinase (Tb11.01.6650) with two sites with a log2
range 5.6 to 4.7, and two CLK dual specificity kinases Tb927.2.4200
(5 sites, log2 range 3.3 to 0.6) and Tb927.10.15020 (4 sites, log2
range 3.2 to 2.4). Two “Other” group protein kinases have
phosphorylation sites that are up-regulated in the procyclic and
bloodstream form, respectively, (Tb927.7.3210, 5 sites, range
log2 −3.7 to 2.8; Tb927.7.3220, 5 sites, range log2 −3.2 to 1.6).
Of the 15 MAPKs present in the T. brucei kinome, 9 (ECK1,
KFR1, MOK, RCK, MAPK2, MAPK9, MAPK10, MAPK12,
and an unnamed MAPK) are shown by the data presented here
to have dual phosphorylation in the TxY motif required for
activation. In addition, multiple phosphorylation sites are ob-
served on three potential upstream STE7 MAP2K and nine STE11
MAP3K protein kinases, suggesting the presence of active MAPK
signaling cascades. The observation of differential phosphorylation
on certain MAPKs, MAP2Ks and MAP3Ks between the two life-
cycle stages suggests that MAPK signaling may play distinct roles in
each lifecycle stage (Figure 7).
Phosphorylation Sites Up-regulated in Bloodstream Form
T. brucei
A total of 203 phosphorylation sites on 119 protein groups
were up-regulated ≥10-fold (Log2 ≤ −3.32) in bloodstream form
T. brucei, with a distribution of these up-regulated phosphorylation
Figure 5. Correlation of fold-changes in protein and fold-changes in phosphorylation sites. (A) Correlation of all phosphorylation sites. (B)
Correlation of average fold-change in phosphorylation sites for each phosphoprotein, with bars indicating the upper and lower limits of the range.
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sites of 74% pS, 15% pT, 11% pY, showing a significant en-
richment in pY compared to the total observations. An addi-
tional 429 sites with no SILAC ratio (on 319 protein groups)
were observed exclusively in the bloodstream form, with the
distribution of 64% pS, 27.5% pT, 8.5% pY showing a similar trend.
These data suggest that tyrosine phosphorylation is significantly
Figure 6. Examples of the assignments of phosphorylation site location from tandem mass spectral data. (A) STE11 family protein kinase
(Tb11.46.003) with pS357 and pS358 with MaxQuant localization score of 1.0 and Mascot delta score of 57.8. (B) CAMK family protein kinase
Tb11.01.2290 with pS5 with MaxQuant localization score of 1.0 and Mascot delta score of 27.1, and pS8 with MaxQuant localization of 1.0 but
which was not identified by Mascot. Data acquired on a LTQ Orbitrap Velos using MSA, * designates loss of phosphate (−98 Da), ** loss of two
phosphates (−196 Da).
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over represented in sites differentially regulated between the
lifecycle stages.
In total, 439 proteins have 631 individual phosphorylation
sites that are either ≥10-fold up-regulated in the bloodstream
form or are bloodstream form specific (Supplemental Table S7,
Supporting Information). This group contains a large number
of proteins annotated as hypothetical or hypothetical conserved,
including 13 of the 15 proteins with >40-fold change (Log2 <
−5.32) at the site level. GO term enrichment of the blood-
stream form up-regulated group (of the 191 annotated proteins
out this total 439) produced a very similar set of enriched terms
to the global phosphoproteome (flagella, protein kinase, and
gene expression), with the addition of terms for glycolysis and
energy metabolism, although this may be due, at least in part, to
large changes at the protein level in some of these proteins.3
Nevertheless, researchers interested in the changes in parasite
metabolism between the procyclic and bloodstream form parasites
are likely to find clues to physiologically relevant phosphorylation
changes in the data provided. Significantly, there are examples
where protein up-regulation in bloodstream form parasites may
be further “amplified” by the coordinate up-regulation of phos-
phorylation. Notable examples of this include the RNA recognition
motif protein RBP10 (Tb927.8.2780) that has been reported to
promote a bloodstream form mRNA expression pattern,23 which
has 4 phosphorylation sites changing by an average of log2 −4.8
(from log2 −5.4 to −4.2), potentially amplifying a change in
protein abundance of Log2 −3.3, and the receptor-type adenylate
cyclase GRESAG4 (Tb927.8.7940) which has 6 phosphorylation
sites changing by an average of log2 −3.9 (from log2 −4.7 to
−3.1), potentially amplifying a change in protein abundance of
log2 −2.4.
Phosphorylation Sites Up-regulated in Procyclic Form T. brucei
A total of 115 phosphorylation sites on 83 protein groups were
≥10-fold up-regulated (log2 ≥ 3.32) in procyclic form T. brucei
with a residue distribution of 70% pS, 22% pT, 9% pY, and an
additional 499 sites with no SILAC ratio on 376 protein groups
were observed exclusively in the procyclic form with a residue
distribution of 77% pS, 15.5% pT, 7.5% pY. The significant
enrichment in pY compared to the total observations mirrors
that seen in the bloodstream form up-regulated phosphorylation
sites, reinforcing the importance of changes in the phosphorylation
of tyrosine between the lifecycle stages.
In total, 459 proteins have 614 individual phosphorylation
sites that are either ≥10-fold up-regulated in the procyclic form
or are procyclic form specific (Supplemental Table S8, Supporting
Information). This procyclic up-regulated group contains a large
number of proteins annotated as hypothetical or hypothetical
conserved, as observed for the bloodstream form up-regulated
group. GO term enrichment of the procyclic up-regulated group
(of 207/460 proteins) again produced a very similar set of
enriched terms to the global and bloodstream form up-regulated
phosphoproteome (flagella, protein kinase, and gene expression)
with no significant new terms. A total of 9 proteins annotated as
transporters have >10-fold change (log2 > 3.32) at the site level,
potentially amplifying the corresponding changes in protein
abundance. Interesting specific examples include: The PAD2
carboxylic acid transporter (Tb927.7.5940), associated with slender
to stumpy bloodstream form transformation in pleomorphic cell
lines,24 where 3 sites increase in phosphorylation with an average
log2 of 3.3 (range log2 1.5 to 6.2) in addition to a protein level
increase of log2 2.9. The ubiquitin carboxy-terminal hydrolase
(Tb927.10.2210), which has 10 phosphorylation sites with an
average log2 of 3.6 (range log2 1.6 to 5.6), while the protein
has almost no change in level (log2 −0.41). The C-14 sterol
reductase (Tb11.01.7170), involved in the biosynthesis of
ergosterol and its isomers that are the principal sterols in the
procyclic parasites,25 has 2 phosphorylation sites with an average
log2 of 3.8 (range log2 3.7 to 3.9), potentially amplifying the
protein fold change of log2 2.2.
Phosphoproteins with Differentially Regulated Sites
A significant number of proteins that are multiply phosphorylated
exhibit phosphorylation sites that are differentially regulated within
the protein between the lifecycle stages (Figure 8). There are
234 proteins (Supplementary Table S9, Supporting Informa-
tion) where the range of fold-changes of phosphorylation sites
within the protein is greater than 10-fold (range Log2 > |3.32|),
with an average of 10 phosphorylation sites per protein. Inter-
estingly, of the 18 proteins where the change in site occupancy
is greater than 80-fold (range Log2 > |6.32|), 16 are annotated
as hypothetical or hypothetical conserved proteins. GO term
Figure 7. Differential phosphorylation of MAPK signaling compo-
nents. Heatmap showing the change in abundance between the
procyclic to bloodstream (Log2) at the protein and phosphorylation
site level for the MAPK, STE7 and STE11 kinase quantified in this
study. Red box, TxY motif; Gray shading, not observed. The Heatmap
is generated with GENEE (http://www.broadinstitute.org/cancer/
software/GENE-E/).
Figure 8. Distribution of intraprotein differentially regulated
phosphorylation sites. Only proteins with more than one phosphor-
ylation site are shown.
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enrichment analysis (of 113/234 proteins) produced signifi-
cantly enriched terms (p < 0.01) including flagellum, gene
regulation, and protein phosphatase activity, but that did not
include protein kinase activity. Three protein phosphatases are
found in the intraprotein differentially regulated group: (i) A
kinetoplastid-specific protein phosphatase (Tb11.01.4320) with
a differential range log2 of |6.6| (10 sites, range log2 −4.8 to 1.8).
(ii) An atypical dual specificity phosphatase (Tb11.01.5870) with a
differential range log2 of |5.6| (3 sites, range log2 −3.8 to 1.7). (iii)
The TFIIF-Stimulated CTD phosphatase (Tb927.10.11450) with
a differential range log2 of |4.1| (4 sites, range log2 −2.1 to 2.0).
■ DISCUSSION
We have previously developed SILAC labeling in procyclic form
T. brucei,3 and here we report the development of SILAC labeling
in the clinically relevant bloodstream form and demonstrate that
growth, morphology and infectivity are unchanged. Both lifecycle
stages are rapidly dividing, enabling efficient isotope incorporation
>98%, and show no propensity to convert arginine to proline.
Two recent proteomic analysis using SILAC labeling in either
procyclic26 or procyclic and bloodstream form27 T. brucei also
observed a similar lack of arginine to proline conversion.
The quantitation of changes in the global phosphoproteome
between procyclic and bloodstream form lifecycle stages of
Trypanosoma brucei, described here, reveals that differential phos-
phorylation is widespread, is not strongly correlated to change in
protein abundance and adds significant complexity to the dif-
ferential expression of the proteome. The observation of intra-
protein differential phosphorylation suggests that phosphor-
ylation may play distinct functional roles in each lifecycle stage,
although how this effect is mediated is at present unclear and,
because of the lack of comparative phosphorylation data to
date, there are few existing hypotheses to examine. However,
one process where protein phosphorylation is suggested to play
a central role is the differentiation of the parasite from blood-
stream to procyclic form in a coordinated, programmed event.28
While we have not studied the actual process of differentiation in
this study, we have examined the phosphoproteomes of the
initial and final states of the process, and observe phosphor-
ylation changes in many of the proteins involved in differen-
tiation. For example, TOR4 (Tb927.1.1930)29 has 10 sites with
log2 changes in the range 0.4−2.7, MAPK5 (Tb927.6.4220)30
has a protein change log2 of 0.5 and pT207 site change log2 of
0.8; ZFK (Tb11.01.1030)31 has a pS520 log2 of −1.3; NOPP44/
46 (Tb927.8.760)32 has a protein log2 of 1.7 and pY5 observed
uniquely in procyclic parasites; PAD2 (Tb927.7.5940)24 has a
protein log2 of 2.9 and 3 sites with log2 in the range 1.5 to 6.2. The
absence of detected phosphorylation on PIP39 (Tb09.160.4480,
protein log2 of 0.9), and PTP1 (Tb927.10.6690, not observed in
our data set) may be due to up-regulation or transient
phosphorylation during differentiation, such as in the division
arrested stumpy form that was not studied here. Alternatively,
the cocktail of phosphatase inhibitors used in this study may
have limited effect against the activity of one or more trypanosome
phosphatase. Clearly, further detailed studies of the process are
required before firm conclusions can be drawn on the precise
rules(s) of protein phosphorylation in trypanosome differentiation.
In this study we have used culture adapted Lister 427
bloodstream form (MITat 1.2) and procyclic form (29.13.6)
cell lines that have been made amenable to genetic mani-
pulation by Wirtz et al. by the insertion of exogenous genes
coding for the T7 RNA polymerase and tetracyclic repressor
protein using either one (bloodstream form) or two (procyclic
form) selectable drug resistance markers.10 The two cell lines
used are independent clones that are not genetically identical,
and this may lead to some differences in protein expression and
phosphorylation status, although such differences are likely to
be minor in comparison to the developmentally regulated changes
between the lifecycle stages. In addition, the culture adapted Lister
427 strains are neither genetically nor morphologically identical to
field isolates, and it is not possible to account for the impact this
will have on protein expression and phosphorylation status.
A significant proportion of the T. brucei kinome of 176
protein kinases are phosphorylated, with individual examples of
phosphorylation sites up-regulated in either procyclic or blood-
stream form, and examples of intraprotein differential phos-
phorylation. The abundance of active MAP kinases, as judged
by the presence of dual TxY motif phosphorylation, suggests
that MAPK pathways are functional in both lifecycle stages of
T. brucei, although how or whether the pathways are regulated
remains unclear. Efforts to determine the detailed biological
role of T. brucei protein kinases are ongoing and knock-down
by RNA interference has provided evidence of the essential
nature of a significant number of protein kinases.33 We have
recently used chemical proteomic profiling to establish that
T. brucei protein kinases are sensitive to typical kinase inhibitors
with nanomolar potency, demonstrating the potential for the
development of species-specific inhibitors.22b Further analysis
of protein kinase mediated phosphorylation cascades by stimulus−
response studies, using the data published here to anchor them,
may reveal the pinch-points that are most suitable for therapeutic
intervention.
Often, eukaryotic phosphorylation signaling cascades terminate
in the modulation of transcription factors to mediate changes in
gene expression. However, classical transcription factors are
missing in T. brucei, where the processing and stability of poly-
cistronically transcribed mRNA precursors appears to regulate
gene expression.5 One potential mechanism to modulate gene
expression in T. brucei is the use of RNA binding zinc finger
proteins to influence mRNA processing and stability, such as
such as ZFP3 (Tb927.3.720)34 and RBP10 (Tb927.8.2780).23
A significant number of ZFPs (31 out of 49) and RBPs (13 out
of 47) are present in the phosphoproteomic data reported here,
with a subset of these (11 and 5, respectively) showing lifecycle
specific regulation of phosphorylation status (≥5-fold change).
Since the dynamic phosphorylation/dephosphorylation of these
proteins has the potential to modulate gene expression, they are
reasonable candidates to be the ultimate effector molecules of
at least some of the trypanosome signaling cascades.
Despite the lack of identifiable dedicated tyrosine kinases in
T. brucei, 234 phosphotyrosine residues were identified, and
tyrosine phosphorylation was 3−4 fold over-represented in the
phosphorylation sites that change between the two lifecycle
stages. Tyrosine phosphorylation is proposed to arise from
putative dual-specificity protein kinases such as DYRK, MEK
and CLK, but there has been no experimental verification of the
dual specificities of the trypanosome kinases to date.
GO term enrichment analysis has revealed that the flagellum
is consistently over-represented among the phosphorylated
proteins. Flagella can play both motility and sensory roles, and
while it is clear that the trypanosome flagellum is highly motile,
its potential sensory role is less well-defined.35 The dynamic
phosphorylation of dynein motors is proposed to control flagella
motility in other organisms, and in trypanosomes flagella motility
is dispensable in the procyclic form but essential for cytokinesis
in the bloodstream form.36 Interestingly, a number of flagella
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proteins show extensive intraprotein differential phosphoryla-
tion, including: (i) dynein heavy chain (Tb927.7.920) with 7
sites with log2 changes in the range −2.8 to 3.2 and protein log2
changes of −0.5; (ii) a paraflagella rod component (Tb927.8.1550)
with 14 sites with log2 changes in the range −3.1 to 2.0 and a
protein log2 change of −0.4; and (iii) an outer dynein docking
complex (Tb11.01.7750) with 3 sites with log2 changes in the
range −3.6 to 1.8 and a protein log2 change of 0.6.
■ CONCLUSIONS
In summary, we have presented a global quantitative phos-
phoproteomic analysis of the bloodstream and procyclic form
of Trypanosoma brucei, which represents both the largest set of
phosphorylation sites and the first report of genome wide
quantitative phosphorylation data for any kinetoplastid. The
establishment of SILAC labeling in both culture-amenable
lifecycle stages of the parasite provides the community with
the tools required to examine signaling events at the molecular
level. This data set reveals the breadth of protein expression
and phosphorylation in T. brucei, and provides a resource for
the community to begin to examine the effect of phosphor-
ylation upon biological processes. The present study of rapidly
dividing nonsynchronized cells provides a static, averaged snapshot
of the basal level of protein phosphorylation, and valuable
information will be gained from future studies of the dynamics
of stimulus-response events such as differentiation.
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